1	MIRS: an AI scoring system for predicting the prognosis
2	and therapy of breast cancer
3	
4	
5	Chen Huang <sup>1,3†</sup> , Min Deng <sup>2†</sup> , Dongliang Leng <sup>2†</sup> , Elaine Lai-Han Leung <sup>1,3</sup> ,
6	Baoqing Sun <sup>4</sup> , Peiyan Zheng <sup>4</sup> , Xiaohua Douglas Zhang <sup>2*</sup>
7	
8	<sup>1</sup> Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, Macau
9	University of Science and Technology, Macau, SAR, China
10	<sup>2</sup> CRDA, Faculty of Health Sciences, University of Macau, Taipa, Macau
11	<sup>3</sup> Stat Key laboratory of Quality Research in Chinese Medicine, Macau Institute For
12	Applied Research in Medicine and Health, Macau University of Science and
13	Technology, Macau, SAR, China
14	<sup>4</sup> Department of Allergy and Clinical Immunology, State Key Laboratory of
15	Respiratory Disease, National Clinical Research Center of Respiratory Disease,
16	Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou
17	Medical University, Guangzhou, Guangdong, China
18	<sup>†</sup> These authors contributed equally to this work
19	*Correspondence: Xiaohua Douglas Zhang douglaszhang@um.edu.mo
20	
21	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 22 Abstract

Current scoring systems for prognosis of breast cancer are available but usually 23 consider only one prognostic feature. We aim to develop a novel prognostic scoring 24 system based on both immune-infiltration and metastatic features to not only assess the 25 patient prognoses more accurately but also guide therapy for patients with breast cancer. 26 Computational immune-infiltration and gene profiling analysis identified a 12-gene 27 panel firstly characterizing immune-infiltrating and metastatic features. Neural network 28 29 model yielded a precise prognostic scoring system called metastatic and immunogenomic risk score (MIRS). The influence of MIRS on the prognosis and 30 therapy of breast cancer was then comprehensively investigated. MIRS significantly 31 stratifies patients into high risk-group (MIRS<sup>high</sup>) and low risk-group (MIRS<sup>low</sup>) in both 32 training and test cohorts. The MIRS<sup>low</sup> patients exhibit significantly improved survival 33 rate compared with MIRS<sup>high</sup> patients. A series of analyses demonstrates that MIRS can 34 35 well characterize the metastatic and immune landscape of breast cancer. Further analysis on the usage of MIRS in chemotherapy suggests that MIRS<sup>high</sup> patients may 36 benefit from three chemotherapeutic drugs (Cisplatin, Tamoxifen and Vincristine). 37 Higher immune infiltration and significantly prolonged survival are observed in 38 MIRS<sup>low</sup> patients, indicating a better response in immune checkpoint inhibitor therapy. 39 Our analysis demonstrates that MIRS could effectively improve the accuracy of 40 41 prognosis for patients with breast cancer. Also, MIRS is a useful webtool, which is deposited at https://lva85.github.io/MIRS/, to help clinicians in designing personalized 42 therapies for patients with breast cancer. 43

Keywords: Breast cancer, Metastasis, Immune infiltration, Prognosis, Personalized
treatment

#### 46 Introduction

47 Cancer has long history in mankind and remains the leading cause of death, with 48 breast cancer being one of the most common malignancies in women worldwide (1, 2). 49 Breast cancer is also the second most common cause of death in cancer-related deaths 50 among women. (3, 4). Despite tremendous advancement of medicine over the years has 51 lowered the mortality rate, the high level of heterogeneity in breast cancer still makes 52 the prognosis and treatment challenging.

Over the decade, a considerable amount of work has been done to develop 53 prognostic measures on the progression of breast cancer (5). The majority (~80%) of 54 breast cancer becomes invasive (6) and approximately 20~30% of them results in 55 distant metastasis after treatment (7). Metastasis is thereby the most fatal development 56 of breast cancer, which greatly reduces the rate of long-term survival from 90% to 5% 57 58 (8). However, most metastasis-based signatures were developed based on organspecific metastatic events, yet breast cancer consists of tumors with extremely 59 heterogeneous cell types, resulting in the discrepancy between prognosis and survival 60 (9, 10). Hence currently available metastasis-based prognostic measures have poor 61 62 performance (11). On the other side, tumor-infiltrating lymphocytes have already been reported to be inextricably linked to therapeutic efficacy and patient survival in various 63 cancers (12, 13). Many prognostic predictors were developed by assessing the level of 64

the infiltration of immune cells into tumor and were preferably adopted for prognosis 65 in cancers (14, 15). These histological strategies based on the analysis of a small 66 67 proportions of immune cell marker genes support the prognostic significance of immune infiltration but still have limitations. Firstly, strategies for describing the level 68 of immune infiltrate are the first limitation of the current studies (16). Specifically, each 69 immune cell subset is computationally estimated by reference profiles based on bulk 70 analysis of tissue samples. This is the main drawback because the transcriptional 71 program of immunocytes exhibits high plasticity under tumor microenvironments (17). 72 73 Secondly, while most studies were used the immune-related characteristics to improve cancer prognosis, only one or two subsets of immunocyte are included and these subsets 74 lack functional variation, thus the treatments based on these indicators fail to achieve 75 76 satisfactory immune response effects (18). Therefore, prognostic indicator based on only one characteristic without considering other crucial features is insufficient to 77 accurately assess risk stratification and direct treatment strategies. 78

79 Given the limitations of the aforementioned work a more comprehensive approach should be developed to assess prognostic value and translate it into clinical practice. 80 81 For the first time, we develop a prognostic signature for breast cancer patients, integrating immune-related gene signatures involved in metastasis, to classify patients 82 83 with breast cancer into groups of high and low risk for potential therapeutic strategies. We construct a Neuron network to estimate gene weights, which exhibit outstanding 84 85 performance in binary classification. A metastatic and immunogenomic risk score (MIRS) is then established, which has conspicuous power to predict survival status 86

compared with previously published indicators based on single feature. Ultimately, the
ability of MIRS to predict the treatment is identified, suggesting its potential to guide
therapeutic tactics in breast cancer.

#### 90 Materials and Methods

#### 91 Collection and pre-processing of breast cancer data

All analyzed expression profiles and the corresponding clinical datasets were collected from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA, https://www.cbioportal.org/datasets), and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC, https://www.cbioportal.org/datasets). Only the datasets available with sufficient overall survival information were included, consisting of 8,424 patients from 14 cohorts. The detailed information of each cohort is presented in Table S1 and S2.

99 Raw series matrix files generated by Affymetrix were downloaded from GEO 100 database. The R package GEOquery (19) was used to process raw matrix data. 101 Duplicated genes detected by multiple probes were retained by taking the maximum 102 expression value of the probe sets. Gene expression value was normalized by log<sub>2</sub> 103 transformation. Each GEO and RNA-seq dataset were processed independently.

#### 104 **Construction of immune cell infiltration groups**

A set of biomarkers is derived from Charoentong et al (20), comprising 45 immune
 signatures related to immune cell types, immunogenomic pathways and functions. The

concrete gene signatures for each immune cell type were obtained from (21), and the 107 immune-related pathways and functions were downloaded from database 'ImmPort' 108 109 (22). Single sample gene set enrichment analysis (ssGSEA) implemented in R package GSVA was used to quantify the infiltration level of different immune cells, 110 111 immunogenomic pathways and the activity of immune-related functions via expression 112 data of breast cancer (23). Based on the results of ssGSEA, patients in TCGA breast cancer cohort (TCGA-BRCA) were divided into high and low immune cell infiltration 113 groups using hierarchical clustering analysis (Figure S1) (24). 114

#### 115 Identification of immune and metastatic candidate

116 **genes** 

Using Wilcoxon rank-sum (Wilcoxon) test, the differentially expressed genes 117 (DEGs) related to tumor immune infiltration were detected from high and low immune 118 infiltration conditions according to the filtering criteria  $|\log 2FC| > 0.5$  and adjusted p < 119 0.05 using Benjamini and Hochberg (BH) method (25). Meanwhile, utilizing the 120 121 Wilcoxon test with the same criteria in the comparison between metastasis and primary breast cancer groups from the union of GSE10893 and GSE3521, the DEGs involved 122 in metastatic mechanism were then identified. For these two DE analyses, Venn 123 analysis found 52 metastatic and immunogenomic candidate genes. The heatmap of 124 these DEGs are visualized in Supplementary Figures S3-S4. 125

### 126 Establishment of prognostic risk score

127	Univariate Cox proportional hazard regression analysis was designed to screen
128	features related to overall survival (OS) from 52 candidate genes in TCGA BRCA
129	cohort. The filtered gene list is provided in Table S2. Subsequently, only the genes with
130	absolute Hazard ratio (HR) larger than 1 and p-value less than 0.05 were retained. To
131	eliminate collinearity, the eligible candidate genes were further filtered depending on
132	the criteria that the square root of Variance Inflation Factor (VIF) was less than 2 and
133	the Pearson Correlation Coefficient was smaller than 0.5. Ultimately, 12 prognostic
134	genes that were significantly correlated with patients' OS were identified.
135	These 12 prognostic signatures were classified into binary status. One was defined
136	as the protective status in which HR was less than 1 whereas another was the dangerous
137	status in which the corresponding HR was greater than 1. The expression status of each
138	protective mRNA was assigned as 1 if the expression level of this mRNA was above
139	the median of the expression values of all samples, otherwise it would be assigned as
140	0. In contrast, the expression of dangerous mRNA was assigned as 1 if it had expression
141	value below median, otherwise assigned as 0. This approach not only allows the risk
142	score, which is based on protective and dangerous genes, to simultaneously contribute
143	to consistent survival outcome, but also avoids the influence of inconsistent sequencing
144	platforms. To date, several machine learning methods were found to be successful in
145	various data mining problems, including those with transcriptomic data (26, 27).

147 the 12 prognostic genes. In the Figure S4, the  $net_{n_1} = W_{1,1}i_1 + W_{2,1}i_2 + \dots +$ 

Therefore, a multilayer perceptron neuron network was built to estimate the weights of

146

 $W_{12,1}i_{12} + b_1$  was defined, where W is the weight of each input node and  $i_i$  (j = 148

1,2,..,12) is the '0-1' status of gene. Then we exploited rectified linear unit (ReLU): 149

150

151 
$$ReLU(net_{n_1}) = Out_{n_1} = \begin{cases} net_{n_1}, & net_{n_1} > 0\\ 0, & net_{n_1} \le 0 \end{cases}$$

152

and  $net_{01} = W'_{1,1} * Out_{n1} + W'_{2,1} * Out_{n2} + W'_{3,1} * Out_{n3} + W'_{4,1} * Out_{n4} + b_2$ 153 as an activation function in the hidden layer. In the output layer, we applied the Softmax 154 function to each node and designated probability of death: 155

156 
$$softmax(net_{01}) = Out_{01} = \frac{e^{net_{01}}}{e^{net_{01}} + e^{net_{02}}} \in (0,1).$$

We then created two nodes  $a_0 = 0$  and  $a_1 = 1$  for alive and dead, respectively. 157 Cross entropy error is computed as: 158

159 
$$E = \sum_{i=1}^{N} E_i = -a_0^i * log(out_{01}^i) - a_1^i * log(out_{02}^i), where i is ith sample.$$

- Finally, the value of each weight was optimized by minimizing E using gradient 160 descent. The R packages Tensorflow and Keras were employed to construct neuron 161 162 network. After training, the coefficient of each prognostic gene was then determined as the maximum weight in the hidden layer (26). 163 Lastly, the risk score that consists of 12 metastatic and immunogenomic prognostic 164
- 165 genes (MIRS) for each patient is defined as the following:

166 
$$MIRS_i = \sum_{j=1}^m weight_j \times I_{\{protective gene j\}} + \sum_{k=1}^n weight_k \times I_{\{dangerous gene k\}}$$

where m and n denote the number of protective and dangerous genes, respectively, 167

- weight is the maximum weight from the hidden layer. Additionally,  $I_{\{protective gene i\}}$ 168
- and  $I_{\{dangerous gene k\}}$  denote the following indicator functions: 169
- 170 I{protective gene

171 
$$=\begin{cases} 1, & Protective gene j < Median expression value across all samples, \\ 0, & otherwise. \end{cases}$$

172  $I_{\{dangerous gene j\}}$ 

173

 $= \begin{cases} 1, & \text{Dangerous gene } k > \text{Median expression value across all samples,} \\ 0, & \text{otherwise.} \end{cases}$ 

#### 174 Statistical analysis

All statistical analyses were performed using R software. The R packages pheatmap and ggplot2 were used to plot heatmap and other graphs. The R package forestplot was used to draw forest plot. The pROC package was employed to generate the Receiver Operating Characteristic (ROC) curve and calculate the Area Under Curve (AUC),

179 which was an indicator to evaluate the predictive performance of risk score.

Based on the risk score, breast cancer patients in the investigated cohort were 180 stratified into subtypes of high risk or low risk depending on whether the value of 181 (MIRS in each patient)/(median of MIRS in all patients) was greater or 182 less than 1. This stratification method allows reasonable comparisons between different 183 data platforms. OS curves were established by Kaplan-Meier survival (KM) curve 184 function ggsurvplot, as implemented in R package survminer, and the difference in 185 186 survival distributions between risk subgroups was estimated by two-side log-rank test. Based on univariate Cox proportional hazard regression analysis, the targeted 187 prognostic genes which were significantly correlated with OS were disclosed and the 188 Hazard ratio (HR), 95% confident interval of HR and p-value were also evaluated. 189 Multivariate Cox proportional hazard regression model was implemented to assess 190 whether the risk score is an independent prognosis factor when compared with other 191 important clinical features. All statistical tests were considered significant with p-value 192

193 < 0.05.

Full details about data and methods descriptions, including data information, geneset enrichment analysis and mutation landscape analysis.

196 **Results** 

#### 197 Screening of candidate genes from three public datasets

To obtain significant prognostic biomarkers in breast cancer, we proposed a 198 systematic scheme of bioinformatic analysis (Figure 1). Given that the processes of 199 metastasis and immune infiltration in tumor play various important roles in cancer 200 development, we hypothesize that the expression of genes which were associated with 201 metastasis and immune infiltration in tumor should be correlated to the OS of cancer 202 203 patients. We thereby identified prognostic signatures based on these two characteristics. Concretely, using ssGSEA method, the expression profile of 1,100 patients from TCGA 204 cohort were used to construct groups of high and low immune cell infiltration. Then the 205 206 patients were classified into the high immune infiltration group and low immune infiltration group (Figure 2A and Figure S1). Furthermore, to validate the reliability of 207 the above grouping tactic, we investigated the expression level of two immune-related 208 gene families between these two groups: CD1 and IL1. As expected, the expression of 209 both immune-related gene families in the high immune infiltration group is 210 significantly higher than that in the low immune infiltration group (Figure 1B and 211 Figure S5). Additionally, compared with low immune cell infiltration group, high 212 immune cell infiltration group exhibits a higher fraction of immune cell, stromal cell 213

but lower tumor purity using ESTIMATE (28) algorithm (Figure 2C). Furthermore, we 214 found that high immune cell infiltration group had significantly higher proportions in 215 216 most immune cell types than low immune infiltration group (Figure 2D) using CIBERSORT algorithm under the permutation test with 1000 times. These findings 217 218 support that our immune cell infiltration grouping is highly confident to be used in downstream analyses. Next, 1,222 differentially expressed genes were identified via 219 differential expression (DE) analysis between these two groups, which represents a 220 high-confidence dataset of genes related to immune infiltration (Table S4). 221

222 On the other part, aimed at identification of metastasis-related candidates, DE analysis between metastasis and primary patients with breast cancer were performed 223 using two GEO cohorts (GSE10893 and GSE3521). The reason why we only chose 224 225 these two GEO datasets is that they have relatively balanced sample sizes between the metastasis and primary groups when compared with other cohorts (Table S1). For 226 instance, TCGA breast cancer cohort contains 1,165 primary individuals but only 23 227 228 metastatic individuals. There is no doubt that such an extremely imbalanced data would lead to biased result in DE analysis. This step yielded a union of 2,159 DE genes from 229 the results of these two GEO datasets (Table S4). Finally, a total of 52 genes was 230 obtained by intersecting 1,222 immune-infiltration-related genes and 2,159 metastasis-231 232 related genes (Figure 2E), which represents prognostic candidates associated with both tumor-immune infiltration (Figure 2F) and metastasis (Figure 2G). 233

#### Construction and validation of MIRS in breast cancer 234 cohorts 235

Univariate Cox regression analyses were performed to estimate the prognostic 236 relationship between candidate genes and overall survival in TCGA cohort. Among 237 these 52 candidate genes, 15 genes with p-value less than 0.05 were selected for follow-238 up study (Table S2). Given that too many redundant variables would result in 239 overfitting in the linear model, we employed the analyses of Variance Inflation Factor 240 and Pearson Correlation Coefficient to eliminate the redundant genes (Figure 3A and 241 3B). As a result, a panel of 12 genes is reserved to establish the predictive model. 242

The TCGA-BRCA data (N = 1100 patients) were randomly classified into training 243 data (N = 770 patients) and testing data (N = 330 patients) at a ratio of 7:3. We then 244 optimized the weights for each gene with Neuron network in the training TCGA data. 245 246 The MIRS for each patient was built by summation of Weight ×  $I_{\{protective or dangerous gene\}}$  of all 12 genes (Table 1). MIRS was initially used to 247 predict patient's survival status, which yielded great predictive performance with AUC 248 accuracy of 0.875 in the training TCGA cohort (Figure 3C). In addition, all the patients 249 were classified into MIRS<sup>high</sup> group and MIRS<sup>low</sup> group using the median value of 250 MIRS as risk cut-off. As shown in Figure 3D, patients in MIRS<sup>low</sup> group had 251 significantly longer OS or disease-free survival (DFS) time than those in MIRS<sup>high</sup> 252 253 group (log-rank p<0.001) (Figure 3D and Figure S6-A).

To further examine the robustness and feasibility of this MIRS model, a 254 comprehensive survival analysis with KM method was performed in three independent 255

256	testing cohorts. Notably, MIRS exhibited robust predictive capacity with AUC of 0.934,
257	0.901, and 0.904 in GSE96058, GSE86166 and GSE20685, respectively (Figure 3E and
258	3G, Supplementary Figure S6-C). Regarding the survival analyses, consistent with the
259	result of the training data, the patients who are divided into MIRS <sup>high</sup> group have
260	significantly worse OS than those in MIRS <sup>low</sup> group (Figure 3F, Figure 3H and
261	Supplementary Figure S6-B). These analyses indicated that MIRS had precisely
262	prognostic ability in breast cancer. The higher score of MIRS corresponds to poor
263	outcome, and the lower score of MIRS refers to favorable outcome.

#### **Correlation of MIRS with the metastatic and**

## 265 immunogenomic landscape between the high and low 266 subtypes

We want to further scrutinize the correlation of metastatic and immunogenomic 267 landscape with MIRS in breast cancer patients. Initially, we investigated the correlation 268 between MIRS and the fraction of immune cell, stromal cell, as well as tumor purity 269 via ESTMATE in the GSE86166 cohort. The results showed that MIRS<sup>low</sup> group had a 270 higher fraction of immune cell and stromal cell cell but a lower tumor purity (Figure 271 4A). Similar situations were observed in GSE96058 (Figure S7). Reasonably, a higher 272 fraction of immune cell and lower tumor purity reflects a high level of infiltrating T-273 lymphocytes in the patients of MIRS<sup>low</sup> group, which is consistent with previous 274 survival analysis. 275

276 Moreover, 730 genes were identified to be correlated to the 12 genes of MIRS

(Spearman Correlation Coefficient  $\geq 0.4$ ) using GSE86166, subsequently, functional 277 enrichment analysis achieved via METASCAPE, indicating various immune-related 278 279 processes and pathways were significantly enriched, including T cell activation, Cytokine-cytokine receptor interaction and B cell activation (Figure 4B). This 280 observation discloses a strong correlation of MIRS with immune activity. Alternatively, 281 we applied ssGSEA analysis to evaluate the immune infiltration level in GSE86166 282 using 17 immune-related biological functions and pathways derived from the immune-283 related database 'ImmPort' (22). The result illustrates that most of the 17 items show 284 significant difference between MIRS<sup>high</sup> and MIRS<sup>low</sup> group (Figure 4C). Notably, all 285 immune-related biological processes and pathways exhibit significantly higher level of 286 immune infiltration in MIRS<sup>low</sup> group (Figure 4C), which is consistent with our 287 288 previous analysis. Moreover, we estimated the correlation of MIRS with three important immune checkpoint molecules: PD-1, PD-L1 and CTLA4. As illustrated in 289 Figure 4E, compared with MIRS<sup>high</sup> group, MIRS<sup>low</sup> group shows significantly higher 290 expression (Wilcoxon test P < 0.0001). MIRS scores are moderately correlated to the 291 expression levels of PD-1, PD-L1 and CTLA4 (Figure 4D). Overall, the differences in 292 tumor immunogenicity between the MIRS groups are significant, MIRS<sup>high</sup> group has 293 relatively low immune infiltration level while MIRS<sup>low</sup> group has relatively high 294 immune infiltration level. Similar results were also observed in TCGA and GSE96058 295 cohort (Supplementary Figure S8). This finding further suggested MIRS<sup>low</sup> group 296 maight have better response in therapy of immune checkpoint blockade. 297

298 To investigate the correlation between MIRS score and metastatic mechanism, we

firstly downloaded the metastasis breast cancer (METABRIC) cohort from human 299 cancer metastasis database https://hcmdb.i-sanger.com/, which contains primary tumor 300 301 and metastatic tumor. Then the functional analysis achieved by GSEA detects 23 qualified metastasis-related gene sets (NES| > 1, NOM p-value < 0.05 and FDR q-value 302 303 < 0.25). After that, ssGSEA analysis was used to evaluate the above significant metastatic pathways. We observe that the metastatic pathways exhibit significant 304 difference between two MIRS groups, and the majority of MIRS<sup>high</sup> group had higher 305 ssGSEA score (Figure 4G). A higher ssGSEA score suggests high activity of metastatic 306 307 processes. Similar results are found in TCGA and GSE96058 cohort (Figure S9-S10). Furthermore, the expression discrepancy of three well-known genes (DCC, MMP9 and 308 ETS) were found to be correlated to the invasion and metastasis in breast cancer (29) 309 310 (Figure 4F), and MIRS exhibits moderately negative correlation with the expression of these genes (Figure 4H). 311

We also examined the relationship between intrinsic molecular subtypes and MIRS. 312 313 In breast cancer, major subtypes based on the ER, PR and HER2 exist on tumor cells. As shown in Figure S15, although the expression levels of ER, PR and HER2 were 314 315 moderately correlated with MIRS, the differences in the expression levels of ER, PR and HER2 between high and low MIRS subtypes were statistically significant in TCGA 316 317 and GSE86166. Additionally, for TCGA cohort, we noticed the imbalanced proportions of intrinsic molecular subtypes between MIRS<sup>high</sup> and MIRS<sup>low</sup> groups (Figure 4I). 318 48.09% of LumA tumor and 22.5% of Normal-like tumor are present in MIRS<sup>high</sup> group 319 whereas 32.33% of LumB tumor in MIRS<sup>10w</sup> subtype. However, we found that higher 320

proportion of Basal-like tumor was present in MIRS<sup>low</sup> subtype. In Muenst et al.' study 321 (30), they pointed out that the number of tumor-infiltrating lymphocytes was the highest 322 323 in the basal-like subtype, which may support a high enrichment of basal-like tumor in MIRS<sup>low</sup> group. We also found that the normal-like had significantly lower MIRS than 324 other molecular subtypes, in contrast to the LumB subtype had the highest MIRS 325 (Figure 4J). In addition, a statistically significant difference was detected among these 326 five intrinsic molecular subtypes by using Kruskal-Wallis method (Figure 4J). 327 Similar results were found in METABRIC cohort (Supplementary Figure S11). These 328 329 analyses indicate that MIRS group exhibited chaotic correlation with classic molecular subtypes, which could be attributed to the high tumorous heterogeneity in breast cancer. 330

### Identification of MIRS related biological characteristics in prognosis of breast cancer

The above analyses implied high correlations between MIRS and tumor-infiltration 333 microenvironment as well as tumor metastasis. We further explore the molecular 334 335 mechanism of 12-gene panel underlying the prognosis of breast cancer. Initially, through literature, we found that the majority of those prognosis-related genes, except 336 for APOA5, has been reported to be involved in the processes of tumorigenesis (Table 337 S6). It is worth mentioning that APOA5, encoding an apolipoprotein, is associated with 338 cardiovascular diseases (31, 32), but little work studies its roles in tumorigenesis and 339 prognosis. To delineate its potential prognostic role in breast cancer, we divided 340 APOA5 expression into four quartiles, then GSEA analysis between the highest and 341

lowers quartiles in TCGA-BRCA was conducted. Interestingly, many metastatic and 342 immune-related pathways were observed to be enriched in the highest quartile, 343 344 including EMT, TNFa signaling and Immune response regulating signaling pathways (Figure 5A and S12A). Subsequent survival analysis of pan-cancer based on TCGA 345 346 cohorts was performed via Kaplan-Meier Plotter (https://kmplot.com/analysis/) (33), indicating that APOA5 may serve as prognostic indicator in many cancers (Figure 347 S12B). The breast cancer patients with the highest APOA5 expression have a worse 348 survival outcome (Figure S12B). Overall, our analysis hinted that APOA5 may exert 349 350 its prognostic function to affect the immune activity in breast cancer, and it is likely to be a potential target for the future research of breast cancer therapy. 351

Genomic mutations are mostly involved in the survival prognosis of various cancers 352 353 (34). Thus, we tested the associations between somatic mutations and MIRS in TCGA BRCA data. According to the analysis in the study of Chen et al (35), only the genes 354 with somatic mutation frequencies more than 2.5% were included. By analyzing the 355 356 mutation annotation of TCGA BRCA cohort, we selected the top 10 genes by mutation frequency. As provided in Figure 5B and C, MIRS<sup>low</sup> group has increased frequency of 357 mutation events than MIRS<sup>high</sup> group. Rizvi et al (36) and Capalbo et al' studies (37) 358 demonstrated that the patients with more mutations might have an increased number of 359 360 neoantigens that enhance response to immunotherapy. This result might explain, in the present study, the reason that MIRS<sup>low</sup> group has better prognostic outcomes than 361 MIRS<sup>high</sup> group. 362

363 Recently, tumor mutation burden (TMB) is the paramount prognostic measure in

364	cancer survival (38). We further investigated the associations between MIRS and TMB.
365	As illustrated in Figure 5D, the patients in MIRS <sup>low</sup> group exhibited markedly increased
366	TMB when compared with those with MIRS <sup>high</sup> group. Lee et al (39) and Karn et al's
367	studies (40) showed that high TMB was associated with improved survival.
368	Additionally, Chen et al (35) reported that the increased TMB was correlated to
369	improved response to PD-1 blockades therapy. Correlation analysis between MIRS and
370	TMB demonstrated that MIRS score was negligibly correlated with TMB (Spearman
371	coefficient: $R = -0.1$ , $p = 0.0011$ ; Figure 5E). These findings indicate that MIRS may
372	be related to immunotherapy response, and the patients with lower MIRS may have
373	probably response in immunotherapy.

#### **The role of MIRS in the prediction of therapeutic**

#### 375 **benefits**

To explore predictive ability of MIRS in immunotherapy for each patient, T cell 376 inflamed score (TIS), IFN -gamma signature, antigen presenting machinery genes 377 (APM) and Immunotherapyscore (IPS) (20, 41, 42), which are prevailing predictors of 378 clinical response to immunotherapy across different tumor types were compared. 379 Notably, the higher of TIS, IFN-gamma score, APM and IPS mean that patients 380 receiving immunotherapy are more likely to response All patients in GSE20711 and 381 GSE58812 with MIRS<sup>low</sup> showed significantly increased predictor scores than those 382 with MIRS<sup>high</sup> (Figure 6A and S13A), which hints that MIRS<sup>low</sup> group is more likely to 383 have immunotherapy response. To further appraise the prognostic capability of 384

MIRS<sup>low</sup> group in immunotherapy, the differences in overall survival between MIRS<sup>high</sup> 385 and MIRS<sup>low</sup> groups were compared using KM survival analysis in breast cancer testing 386 387 cohort. Unfortunately, there are hitherto few public datasets of breast cancer patients receiving immunotherapy. Instead, the data of melanoma from Liu et al (43) and 388 TCGA-SKCM dataset with patient receiving immunotherapy were used in present 389 analysis. As a result, compared with PD-1 and TMB biomarkers upon receiving anti-390 PD-1 treatment, MIRS showed robust AUCs (Figure 6B-D). Furthermore, the patients 391 with MIRS<sup>high</sup> have significantly shorter overall survival than their counterparts (Figure 392 393 6E and Figure S13B). MIRS significantly increases in patients with stable disease (SD) or progressive disease (PD) when compared with those with complete response (CR) 394 or partial response (PR) (Figure 6F and Figure S13CB). Besides, the distributions of 395 CR/PR and SD/PD across MIRS<sup>high</sup> and MIRS<sup>low</sup> groups were also validated. We found 396 that patients in MIRS<sup>low</sup> group had better response to immunotherapy than those in 397 MIRS<sup>high</sup> group (Figure 6G and Figure S13DC). 398

399 Moreover, to assess therapeutic value of MIRS in chemotherapy, we examined its predictive potential in GSE20685 with the breast cancer patients who receive adjuvant 400 chemotherapy. The optimal cutoffs of MIRS were determined by the median cutoff, 401 then the patients were stratified into MIRS<sup>high</sup> and MIRS<sup>low</sup> group. Survival analysis 402 displays that the breast cancer patients with MIRS<sup>low</sup> had much better survival than 403 those with MIRS<sup>high</sup> in adjuvant chemotherapy cases (Figure 6H). We also investigated 404 the prognosis of different MIRS subtypes with or without adjuvant chemotherapy. As 405 illustrated in Figure 6I, we found that MIRS<sup>high</sup> group had statistically significant 406

differences between the patients who were treated with adjuvant chemotherapy and 407 those without adjuvant chemotherapy. However, a consistent result was not observed 408 in those patients with MIRS<sup>low</sup> (Figure 6J). These results indicated that adjuvant 409 chemotherapy might be more beneficial to MIRS<sup>high</sup> group. Based on the gene sets of 410 411 different drug treatments retrieved from MSigDB database, GSEA predicted that MIRS<sup>high</sup> was significantly correlated with drug sensitivity in TCGA cohort (Figure 6K). 412 Moreover, the R package pRRophetic was used to estimate the sensitivity of three 413 chemotherapeutic drugs, including cisplatin, tamoxifen and vincristine, which have 414 415 been commonly used in breast cancer treatment. The results showed that estimated IC50 values of cisplatin and vincristine significantly decrease in MIRS<sup>high</sup> subtype (Figure 416 6L). We did not display IC50 boxplot of tamoxifen due to the R package 'pRRophetic' 417 418 does not contain resistant information regarding tamoxifen. These results suggest that MIRS holds massive potential for predicting the response 419

to chemotherapy and immunotherapy in breast cancer patients. In brief, the patients
 with MIRS<sup>high</sup> may benefit from the chemotherapy, and patients with MIRS<sup>low</sup> are likely
 to be more sensitive to the immunotherapy.

423

# 424 Comparison of MIRS with the previously prognostic 425 models

Before the creation of MIRS, Shimizu et al (26) demonstrated that 23-gene panel
(mPS) helps predict OS in breast cancer patients based on analogous neuron network

model; Cui's score (44) constructed 8-gene signature based on traditional Lasso Cox
model. We then comprehensively evaluate the prognostic power of our MIRS, mPS and
Cui's score by 0prognostic Cox analyses based on a variety of public datasets. Our
MIRS performed very well in different cohorts (Figure 7A). Although mPS showed to
be more robust than MIRS in many datasets, some of the HRs in mPS panel were not
significant (P value > 0.05) (Figure 7B). Cui's score performed the worst among these
models (Figure 7C).

Furthermore, we scrutinized the predictive potential of these three models in the 435 436 response to immunotherapy. The malignant melanoma cohort data (43) that receives anti-PD-1 therapy was used. The optimal cutoffs of Cui's score and mPS value were 437 determined by the median. KM survival curves of MIRS show a significant difference 438 in OS between MIRS<sup>high</sup> and MIRS<sup>low</sup> group (Figure 7E). On the contrary, the survival 439 analysis of mPS and Cui's score revealed that patients with low mPS or Cui's score 440 showed no statistically significant difference when compared with those with high 441 442 mPS or Cui's score (Figure 7F-G). MIRS, mPS and Cui's score were also examined with time-dependent ROC analysis in the testing cohort for prediction in 443 immunotherapeutic benefits. Notably, our MIRS exhibited much better predictive 444 ability than mPS and Cui's score for OS at 1 year, 1.5 years, and 2 years, respectively 445 (Figure 7D). 446

#### 447 **Discussion**

448 With the development of transformative technologies, analyses of high throughput

sequencing data have significantly deepened the understanding of modern biology, 449 enabling the scientists to thoroughly explore key characteristics in a variety of cancers. 450 451 Metastasis and tumor-immune infiltration are two of the major characteristics, and have been extensively proven to be associated with tumorigenesis, drug resistance and 452 prognosis in breast cancer (43). Quite a few studies have disclosed the roles of 453 metastasis and tumor-immune infiltration as prognostic factors in predicting the 454 survival outcomes for breast cancer (45). Unfortunately, breast tumors are highly 455 heterogeneous among individuals, and much current work has only considered organ-456 457 specific metastasis or immune infiltration level and thus insufficient to achieve robust predictive power on prognosis. To address this issue, in this study we developed a 458 comprehensive and efficient prognosis model, considering metastasis and immune 459 460 infiltration levels together, to aid clinicians in providing precise treatment strategies.

Given the promising predictive value of MIRS, we systematically investigated the 461 relationships between MIRS and clinical pathological characteristics. In different 462 463 sequencing platform data, MIRS demonstrated as an independent prognosis factor compared with other conventional clinical features (Figure S14). As illustrated in 464 Figure S17A, we observed differences between MIRS and Age, Gender and Metastasis 465 variables. Subsequently, we used decision curve analysis (DCA) to decipher the effect 466 in combining MIRS with clinical indicators. In the DCA analysis, the net benefit of 467 clinical indicators combined with MIRS were better than of sole clinical indicator 468 (Figure S17B). Additionally, we employed TCGA and GSE96058 datasets to 469 investigate whether MIRS is suitable for all BRCA subtypes due to its complete subtype 470

471 information. However, we have not observed consistently predictive ability in both
472 datasets (Figure S18). This unsatisfied performance may come from the fact that we
473 built our MIRS model without tumor subtype information. Together, these results
474 demonstrate the validity and reliability of MIRS in clinical applications, but it no
475 suitable to all subtypes in breast cancer.

Next, we compared MIRS with the representative prognostic models, mPS and 476 Cui's score. Univariate cox regression analysis using nine public cohorts indicated that 477 MIRS and mPS performd well in most cohorts. These results indicated that, 478 479 constructing a prognostic system considering only metastatic features may be insufficient. Compared with AI methods, traditional survival model showed weak 480 power. Nonetheless, mPS scoring system, based on an analogous AI approach, does not 481 482 work well in predicting immunotherapeutic. It might explain that the establishment of mPS does not consider immunogenomic features, thus failing to achieve satisfactory 483 immunotherapeutic prediction. 484

485 Apart from being informative regarding prognosis, MIRS can also act as an independent predictor to guide therapeutic strategies. Our analyses indicated that 486 MIRS<sup>high</sup> group had lower TIS, IPS, IFN-gamma score and APM score, implying 487 MIRS<sup>high</sup> group is more likely to escape from immunity in breast cancer. For further 488 validation, we tested if the OS between MIRS<sup>high</sup> and MIRS<sup>low</sup> groups was associated 489 with immunotherapy. We used two malignant melanoma cohorts 490 with immunotherapeutic information by conducting KM analysis. This survival analysis 491 showed that MIRS<sup>low</sup> group exhibited improved survival and better response to 492

493 immunotherapy than MIRS<sup>high</sup>. We speculate that the immunotherapy may achieve
494 beneficial treatment for MIRS<sup>low</sup> patients.

495 Currently, chemotherapy is one of the main treatments for breast cancer. Hence, it is necessary to identify patients who may potentially benefit from chemotherapy. 496 Through the analysis of breast cancer patients with chemotherapy clinical 497 information, we found that patients with MIRS<sup>high</sup> respond better to chemotherapy than 498 patients with MIRS<sup>low</sup>. Chemotherapy has been reported to be related to immune 499 infiltration (46). In the Ahn et al's study (47), they demonstrated that the high level of 500 501 the CD8+ TILs filtration is associated with chemotherapy resistance. This may be the reason that high filtration MIRS<sup>low</sup> subtype shows favorable chemotherapy. These 502 results emphasize the significance of MIRS<sup>high</sup> patients who could benefit from 503 504 chemotherapy.

As a gene prognostic signature particularly designed for breast cancer patients, 505 MIRS is a novel and robust approach in risk stratification and personalized treatment. 506 507 However, there are still flaws in the current study. First, due to the remarkable intratumor heterogeneity in breast cancer, we cannot cover all metastatic signatures despite 508 a large numbers of breast cancer patients used in this study. Second, only the median 509 cutoff of MIRS is used to classify the patients into high and low subtypes, the optimal 510 cutoff of MIRS would be needed to provide rational strategies. Lastly, all the 511 conclusions in this research are obtained from *in silico* studies, clinical experiments are 512 required to confirm our findings. 513

514 MIRS has the potential to assist oncologists to screen patients who are more likely

- 515 to benefit from immunotherapy or chemotherapy. It would be of great significance to
- validate the value of MIRS in prospective clinical trials.

#### 517 **Contributors**

- 518 CH and XDZ conceived the presented idea. CH, DLL and MD collected the public data,
- 519 MD and CH developed the methodology, MD and DLL analyzed the data under the
- supervision of CH. CH and MD took the lead in drafting the manuscript with input from
- all authors. CH, ELHL and XDZ revised the manuscript, PYZ and BQS interpreted
- results from a clinical point of view. All authors read and approved the final manuscript.

#### 523 **Declaration of competing interests**

524 The authors have declared that no competing interest exists

#### 525 Acknowledgements

- 526 This work was supported by Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery
- 527 (File no. 001/2020/ALC), by the Science and Technology Development Fund, Macau
- 528 Government (File no. 0020/2021/A), by the University of Macau (grant numbers: FHS-CRDA-
- 529 029-002-2017 and MYRG2018-00071-FHS), Zhongnanshan Medical Foundation of
- 530 Guangdong Province (grant number: ZNSA-2021016) and the Science and Technology
- 531 Development Fund, Macau SAR (File no. 0004/2019/AFJ and 0011/2019/AKP).

#### All fights reserved. No reuse allowed without permi

#### 532 Data sharing statement

533	Data are available in a public, open access repository. All used data in the current study
534	are downloaded from Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.
535	gov/geo/) and The Cancer Genome Atlas (TCGA) database (https:// cancergenome. nih.
536	gov/).

#### 537 **References**

1. Dumas A, Vaz Luis I, Bovagnet T, El Mouhebb M, Di Meglio A, Pinto S, et al. 538 Impact of Breast Cancer Treatment on Employment: Results of a Multicenter 539 540 Prospective Cohort Study (CANTO). J Clin Oncol. 2020;38(7):734-43. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 541 2. 2018;68(1):7-30. 542 3. Afifi AM, Saad AM, Al-Husseini MJ, Elmehrath AO, Northfelt DW, Sonbol MB. 543 Causes of death after breast cancer diagnosis: A US population-based analysis. 544 545 Cancer. 2020;126(7):1559-67. 546 4. Gansler T, Ganz PA, Grant M, Greene FL, Johnstone P, Mahoney M, et al. Sixty years of CA: a cancer journal for clinicians. CA Cancer J Clin. 2010;60(6):345-50. 547 Landemaine T, Jackson A, Bellahcene A, Rucci N, Sin S, Abad BM, et al. A six-gene 548 5. signature predicting breast cancer lung metastasis. Cancer research. 549

550 2008;68(15):6092-9.

Scott E. Androgen deprivation with or without radiation therapy for clinically
 node-positive prostate cancer. Lin CC, Gray PJ, Jemal A, Efstathiou JA, Surveillance
 and Health Services Research Program, Intramural Research, American Cancer
 Society, Atlanta, GA (CCL, AJ); Department of Radiation Oncology, Massachusetts
 General Hospital, Harvard Medical School, Boston, MA (PJG, JAE); e-mail:
 jefstathiou@partners.org. J Natl Cancer Inst. 2015 May 9;107(7). pii: djv119. [Print
 2015 Jul]. doi: 10.1093/jnci/djv119. Urol Oncol. 2017;35(3):122-3.

558 7. Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and
559 hormonal therapy for early breast cancer on recurrence and 15-year survival: an
560 overview of the randomised trials. Lancet. 2005;365(9472):1687-717.

 Seenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Longterm follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14(8):2197-205.
 Cremasco V, Astarita JL, Grauel AL, Keerthivasan S, MacIsaac K, Woodruff MC, et

al. FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in
 Immune-Excluded Breast Tumors. Cancer Immunol Res. 2018;6(12):1472-85.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.16.21267775; this version posted December 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. All rights reserved. No reuse allowed without permission.

10. Landemaine T, Jackson A, Bellahcene A, Rucci N, Sin S, Abad BM, et al. A six-gene 567 signature predicting breast cancer lung metastasis. Cancer Res. 2008;68(15):6092-9. 568 11. Li J, Lenferink AE, Deng Y, Collins C, Cui Q, Purisima EO, et al. Identification of 569 high-quality cancer prognostic markers and metastasis network modules. Nat 570 Commun. 2010;1:34. 571 12. Xiao Z, Hu L, Yang L, Wang S, Gao Y, Zhu Q, et al. TGFbeta2 is a prognostic-572 related biomarker and correlated with immune infiltrates in gastric cancer. J Cell Mol 573 Med. 2020;24(13):7151-62. 574 13. Shen Y, Peng X, Shen C. Identification and validation of immune-related IncRNA 575 576 prognostic signature for breast cancer. Genomics. 2020;112(3):2640-6. 577 14. Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells 578 are associated with clinical outcome in metastatic melanoma. Cancer Res. 579 2012;72(5):1070-80. 580 15. Yang L, Wang S, Zhang Q, Pan Y, Lv Y, Chen X, et al. Clinical significance of the 581 immune microenvironment in ovarian cancer patients. Mol Omics. 2018;14(5):341-582 51. 583 16. Barnes TA, Amir E. HYPE or HOPE: the prognostic value of infiltrating immune 584 cells in cancer. British journal of cancer. 2017;117(4):451-60. 585 17. Pérez-Romero K, Rodríguez RM, Amedei A, Barceló-Coblijn G, Lopez DH. Immune 586 Landscape in Tumor Microenvironment: Implications for Biomarker Development 587 and Immunotherapy. International Journal of Molecular Sciences. 2020;21(15):5521. 588 589 18. Liu R, Hu R, Zeng Y, Zhang W, Zhou H-H. Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer 590 591 subtypes: A gene expression-based computational study. EBioMedicine. 2020;51:102602. 592 19. Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus 593 (GEO) and BioConductor. Bioinformatics. 2007;23(14):1846-7. 594 595 20. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype 596 relationships and predictors of response to checkpoint blockade. Cell reports. 597 2017;18(1):248-62. 598 21. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. 599 Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype 600 601 Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017;18(1):248-62. 602 22. Bhattacharya S, Dunn P, Thomas CG, Smith B, Schaefer H, Chen J, et al. ImmPort, 603 604 toward repurposing of open access immunological assay data for translational and clinical research. Sci Data. 2018;5:180015. 605 23. Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for 606 607 microarray and RNA-seq data. BMC bioinformatics. 2013;14(1):7. 24. Gentleman R, Carey VJ. Unsupervised machine learning. Bioconductor case 608 609 studies: Springer; 2008. p. 137-57. 25. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and 610

powerful approach to multiple testing. Journal of the Royal statistical society: series 611 B (Methodological). 1995;57(1):289-300. 612 26. Shimizu H, Nakayama KI. A 23 gene–based molecular prognostic score precisely 613 predicts overall survival of breast cancer patients. EBioMedicine. 2019;46:150-9. 614 27. Agarap AF. Deep learning using rectified linear units (relu). arXiv preprint 615 616 arXiv:180308375.2018. 28. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, 617 et al. Inferring tumour purity and stromal and immune cell admixture from 618 expression data. Nature communications. 2013;4(1):1-11. 619 620 29. Wakita K, Kohno N, Sakoda Y, Ishikawa Y, Sakaue M. Decreased expression of the 621 DCC gene in human breast carcinoma. Surgery today. 1996;26(11):900-3. 30. Muenst S, Soysal S, Gao F, Obermann E, Oertli D, Gillanders W. The presence of 622 623 programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast cancer research and treatment. 624 2013;139(3):667-76. 625 31. Dallongeville J, Cottel D, Montaye M, Codron V, Amouyel P, Helbecque N. Impact 626 of APOA5/A4/C3 genetic polymorphisms on lipid variables and cardiovascular 627 disease risk in French men. International journal of cardiology. 2006;106(2):152-6. 628 32. Lin Y-C, Nunez V, Johns R, Shiao SPK. APOA5 gene polymorphisms and 629 cardiovascular diseases: metaprediction in global populations. Nursing research. 630 2017;66(2):164-74. 631 33. Nagy Á, Munkácsy G, Győrffy B. Pancancer survival analysis of cancer hallmark 632 633 genes. Scientific reports. 2021;11(1):1-10. 34. Gotea V, Gartner JJ, Qutob N, Elnitski L, Samuels Y. The functional relevance of 634 somatic synonymous mutations in melanoma and other cancers. Pigment cell & 635 melanoma research. 2015;28(6):673-84. 636 35. Chen Z, Yuan Y, Chen X, Chen J, Lin S, Li X, et al. Systematic comparison of 637 somatic variant calling performance among different sequencing depth and mutation 638 639 frequency. Scientific reports. 2020;10(1):1-9. 640 36. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung 641 cancer. Science. 2015;348(6230):124-8. 642 37. Capalbo C, Scafetta G, Filetti M, Marchetti P, Bartolazzi A. Predictive biomarkers 643 644 for checkpoint inhibitor-based immunotherapy: the galectin-3 signature in NSCLCs. International journal of molecular sciences. 2019;20(7):1607. 645 38. Riviere P, Goodman AM, Okamura R, Barkauskas DA, Whitchurch TJ, Lee S, et al. 646 High tumor mutational burden correlates with longer survival in immunotherapy-647 naïve patients with diverse cancers. Molecular Cancer Therapeutics. 648 2020;19(10):2139-45. 649 39. Lee D-W, Han S-W, Bae JM, Jang H, Han H, Kim H, et al. Tumor mutation burden 650 651 and prognosis in patients with colorectal cancer treated with adjuvant fluoropyrimidine and oxaliplatin. Clinical Cancer Research. 2019;25(20):6141-7. 652 40. Karn T, Denkert C, Weber K, Holtrich U, Hanusch C, Sinn B, et al. Tumor 653 mutational burden and immune infiltration as independent predictors of response to 654

- All rights reserved. No reuse allowed without permission.
- neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. Annals of 655 Oncology. 2020;31(9):1216-22. 656 41. Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, et al. IFN-657 v-related mRNA profile predicts clinical response to PD-1 blockade. The Journal of 658 clinical investigation. 2017;127(8):2930-40. 659 42. Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, et al. A 660 consensus molecular classification of muscle-invasive bladder cancer. European 661 urology. 2020;77(4):420-33. 662 43. Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Amon L, et al. Integrative 663 molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with 664 665 metastatic melanoma. Nature medicine. 2019;25(12):1916-27. 44. Cui Q, Tang J, Zhang D, Kong D, Liao X, Ren J, et al. A prognostic eight - gene 666 expression signature for patients with breast cancer receiving adjuvant 667 chemotherapy. Journal of cellular biochemistry. 2020;121(8-9):3923-34. 668 45. Wang S, Zhang Q, Yu C, Cao Y, Zuo Y, Yang L. Immune cell infiltration-based 669 signature for prognosis and immunogenomic analysis in breast cancer. Briefings in 670 671 bioinformatics. 2020. 46. Mesnage S, Auguste A, Genestie C, Dunant A, Pain E, Drusch F, et al. 672 Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed 673 death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Annals of 674
- 675 Oncology. 2017;28(3):651-7.
- 47. Ahn S, Chung YR, Seo AN, Kim M, Woo JW, Park SY. Changes and prognostic
- values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in
- breast cancer. PloS one. 2020;15(5):e0233037.
- 679

#### 680 **Tables**

### Table 1. The 12 prognostic genes for calculating the risk score in TCGA data

Gene ID	Category	Gene expression (high)	Gene expression (low)	Weight
APOA5	Dangerous	1	0	0.4703
FAM9C	Dangerous	1	0	0.5585
IVL	Dangerous	1	0	0.4467
PAGE5	Dangerous	1	0	0.5637
CACNA1E	Protective	0	1	0.3596
CCL25	Protective	0	1	0.5013
CD1A	Protective	0	1	0.1782
CD1B	Protective	0	1	0.7733
GPR55	Protective	0	1	0.6999

LAX1	Protective	0	1	0.6383
TNFRS	F8 Protective	0	1	0.6234
WNT10	A Protective	0	1	0.4189

683

684

#### **Figure Legends** 685

686
-----

687 688	Fig	ure 1. Systematic bioinformatic analysis pipeline.		
689	Figure 2. Exploration of the immune cell infiltration grouping, and 52 candidate			
690	genes were expressed in BRCA samples from the TCGA. GSE10893. and			
691	GS	E3521 datasets.		
692	(A)	Heatmap for the high and low immune-cell infiltration grouping from the TCGA cohort.		
693	<b>(B)</b>	Boxplots for the expression levels of the CD family gene between high and low infiltration groups.		
694	( <b>C</b> )	Comparison of Stromal score, Immunity score, ESTIMATE score and Tumor purity between the		
695	higł	and low immune infiltration groups.		
696	( <b>D</b> )	Boxplots illustrate the 22 immune cell proportion s between high and low immune infiltration		
697	grou	ıps.		
698	<b>(E)</b>	Venn plot of the differentially expressed genes from the TCGA data and GEO datasets.		
699	<b>(F)</b>	Heatmap of the 52 candidate gene expression values between high and low immune infiltration		
700	grou	ups from the TCGA dataset. Cluste1 represents the low immune infiltration level group, cluster 2		
701	repr	esents the high immune infiltration level group.		
702	( <b>G</b> )	Volcano plot of the 52 candidate genes between the primary and metastasis tumor groups both		
703	from	n the GSE3521 and GSE10893. The blue dots show the DE genes are down regulated in the		
704	met	astasis group. The red dots display the DE genes are up regulated in the metastasis group. The p-		
705	values were calculated using Wilcox rank sum test.			
706				
707	Fig	ure 3. Construction and validation of the MIRS in the training and testing		
708	coh	iorts.		
709	A.	The square root of the variance inflation factor value for each candidate gene in the training		
710		data.		
711	B.	Correlations between the candidate genes in the training TCGA data. Different correlations		
712		between two genes are represented by different colors.		
713	C.	ROC curve for the patient's overall survival prediction in the training TCGA data.		
714	D.	Kaplan-Meier curves of overall survival according to the MIRS subtypes in the training TCGA		
715		data.		
716	Е.	ROC curve for the patient's overall survival prediction in GSE96058.		
717	F.	Kaplan-Meier curves of overall survival according to the MIRS subtypes in GSE96058.		
718	G.	ROC curve for the patient's overall survival prediction in GSE86166.		
719	H.	Kaplan-Meier curves of overall survival according to the MIRS subtypes in GSE86166.		
720				

721 722	Fig lan	ure 4. Correlation of MIRS with the metastatic and immunogenomic dscape between the high and low MIRS subtypes.
723	A.	Comparison of the Stromal score. ESTIMATE score. Immune score, and Tumor purity between
724		high and low MIRS subtypes in GSE86166. The p-values were calculated using Wilcoxon rank
725		sum test. * $p<0.05$ ; ** $p<0.01$ ; *** $p<0.0001$ .
726	B.	Function enrichment bar plot for the genes in GSE86166 which were highly correlated
727		(Spearman correlation coefficient $\geq 0.04$ ) with 12 prognostic genes in GSE86166.
728	C.	Boxplots of the ssGSEA score for 17 immune-related biological functions and pathways
729		between two MIRS subtypes in the GSE86166. The p-values were calculated using Wilcoxon
730		rank sum test. *p<0.05; **p<0.01; ***p<0.0001.
731	D.	The spearman correlation between the gene expression levels of PD-1, PD-L1 and CTLA4 and
732		MIRS score in the GSE86166 data, respectively.
733	E.	The boxplots of PD-1, PD-L1 and CTLA4 for two MIRS subtypes in the GSE86166 data. The
734		p-values were calculated using Wilcoxon rank sum test. *p<0.05; **p<0.01; ***p<0.0001.
735	F.	The boxplots of DCC, MMP9 and ETS1 for two MIRS subtypes in GSE86166 dataset. The p-
736		values were calculated using Wilcoxon rank sum test. *p<0.05; **p<0.01; ***p<0.0001.
737	G.	Boxplots of the ssGSEA score for 23 metastatic biological functions and pathways between two
738		MIRS subtypes in the GSE86166. The p-values were calculated using Wilcoxon rank sum test.
739		*p<0.05; **p<0.01; ***p<0.0001.
740	H.	The spearman correlation between the gene expression levels of DCC, MMP9 and ETS1 and
741		MIRS score in the GSE86166, respectively.
742	I.	Sankey diagram for the MIRS values with different intrinsic molecular subtypes in TCGA
743		patients.
744	J.	Violin plots for the distribution of MIRS values in different intrinsic molecular subtypes at
745		TCGA BRCA cohort. The p-values were calculated using Kruskal-Wallis test. $p<0.05$ ;
746		**p<0.01; ***p<0.0001.
747		
748	Fig	ure 5. Identification of MIRS-related biological characteristics in prognosis of
749	bre	east cancer.
750	A.	GSEA enrichment plots in TCGA.
751	В.	The Oncoplot of top 10 genes with the highest mutation frequency in high MIRS group (TCGA
752	-	data).
753	C.	The Oncoplot of top 10 genes with the highest mutation frequency in low MIRS group (TCGA
754	_	data).
755	D.	Boxplots of the MIRS score between the high and low TMB subtypes in TCGA data. The p-
756	-	values were calculated using Wilcoxon rank sum test.
757	E.	The spearman correlation between the MIRS score and TMB values in TCGA data.
758		
759	Fig	ure 6. The therapeutic benefit of the MIRS value.
760 761	А.	I he boxplot of TIS, IPS, APM score and IFN gamma score between the high and low MIRS in GSE20711.
762	B.	ROC curves between the expression level of PD-1. TMB and MIRS of anti-PD1
763	2	immunotherapy response prediction in Liu et al data.
764	C.	Time-dependent ROC curves of MIRS for anti-PD1 immunotherapy response prediction in the
		- 17 1

765		Liu et al data.
766	D.	Time-dependent ROC curves of the expression level for anti-PD1 immunotherapy response
767		prediction in Liu et al data.
768	E.	Kaplan-Meier curves of overall survival according to MIRS subtypes in the Liu et al data.
769	F.	Violin plot illustrating the distribution of MIRS for patients with different immunotherapy
770		response in Liu et al data.
771	G.	Bar graph showing the number of clinical responses to anti-PD-1 immunotherapy in the high
772		and low MIRS subtypes in Liu et al data.
773	H.	Kaplan-Meier curves of overall survival according to MIRS subtypes with chemotherapy in
774		GSE20685.
775	I.	Kaplan-Meier curves of overall survival according to the high MIRS subtype with or without
776		chemotherapy in GSE20685.
777	J.	Kaplan-Meier curves of overall survival according to the low MIRS subtype with or without
778		chemotherapy in GSE20685.
779	K.	GSEA predict that high MIRS group is negatively correlated with drug resistance in TCGA
780		cohort.
781	L.	Chemotherapeutic sensitivity of two drugs (Cisplatin, Vincristine) were estimated and
782		compared in TCGA cohort.
783		
784	Fig	ure 7. Compare MIRS with previous prognosis signatures.
785	A.	A meta-analysis was performed using the prognosis results of MIRS in nine public datasets.
786	В.	A meta-analysis was performed using the prognosis results of mPS in nine public datasets.
787	C.	A meta-analysis was performed using the prognosis results of Cui's score in nine public
788		datasets.
789	D.	Time-dependent ROC curves of anti-PD-1 immunotherapy on the 1-,1.5-,2-year survival rates
790		for Liu et al data.
791	E.	Kaplan-Meier curves of overall survival according to MIRS subtype with immunotherapy in
792		Liu et al data.
793	F.	Kaplan-Meier curves of overall survival according to mPS subtype with immunotherapy in Liu
794		et al data.
795	G.	Kaplan-Meier curves of overall survival according to Cui's score subtype with immunotherapy
796		in Liu et al data.









medRxiv preprint doi: https://doi.org/10.1101/2021.12.16.21267775; this version posted December 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.















B







**Cui's Score** 



D







F

G



Α